Geron reported $468.74M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Amgen USD 34.36B 598M Sep/2026
Bio Techne USD 824.83M 80.43M Sep/2026
Cassava Sciences USD 80.06M 3.67M Sep/2026
Cytokinetics USD 1.19B 21.34M Sep/2026
Exelixis USD 1.32B 70.8M Sep/2026
Genmab DKK 2.8B 228M Jun/2026
Geron USD 468.74M 17.6M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
MacroGenics USD 295.08M 26.61M Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Novavax USD 707.96M 63.14M Sep/2026